Matinas Biopharma (MTNB) Competitors $0.55 -0.02 (-3.81%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends MTNB vs. SNSE, TSBX, PHXM, JAGX, INDP, CLRB, MYNZ, CYCN, EGRX, and BCDAShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Sensei Biotherapeutics (SNSE), Turnstone Biologics (TSBX), PHAXIAM Therapeutics (PHXM), Jaguar Health (JAGX), Indaptus Therapeutics (INDP), Cellectar Biosciences (CLRB), Mainz Biomed (MYNZ), Cyclerion Therapeutics (CYCN), Eagle Pharmaceuticals (EGRX), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Sensei Biotherapeutics Turnstone Biologics PHAXIAM Therapeutics Jaguar Health Indaptus Therapeutics Cellectar Biosciences Mainz Biomed Cyclerion Therapeutics Eagle Pharmaceuticals BioCardia Matinas Biopharma (NYSE:MTNB) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends. Which has more volatility and risk, MTNB or SNSE? Matinas Biopharma has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Is MTNB or SNSE more profitable? Sensei Biotherapeutics' return on equity of -53.86% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Sensei Biotherapeutics N/A -53.86%-46.91% Which has stronger valuation & earnings, MTNB or SNSE? Matinas Biopharma has higher revenue and earnings than Sensei Biotherapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas Biopharma$1.10M2.52-$22.94M-$4.85-0.11Sensei BiotherapeuticsN/AN/A-$34.10M-$1.19-0.38 Does the MarketBeat Community believe in MTNB or SNSE? Sensei Biotherapeutics received 27 more outperform votes than Matinas Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformMatinas BiopharmaN/AN/ASensei BiotherapeuticsOutperform Votes2779.41% Underperform Votes720.59% Do analysts prefer MTNB or SNSE? Sensei Biotherapeutics has a consensus target price of $4.33, indicating a potential upside of 863.18%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in MTNB or SNSE? 11.8% of Matinas Biopharma shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 9.6% of Matinas Biopharma shares are held by company insiders. Comparatively, 22.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer MTNB or SNSE? In the previous week, Matinas Biopharma's average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score. Company Overall Sentiment Matinas Biopharma Neutral Sensei Biotherapeutics Neutral SummarySensei Biotherapeutics beats Matinas Biopharma on 8 of the 13 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.77M$6.57B$5.12B$19.18BDividend YieldN/A2.98%4.91%3.59%P/E Ratio-0.1110.5991.3441.28Price / Sales2.52195.381,116.5917.59Price / CashN/A57.1642.6421.28Price / Book0.125.104.795.32Net Income-$22.94M$151.51M$120.07M$989.88M7 Day Performance-4.05%-2.15%-1.89%-3.54%1 Month Performance-3.64%-3.14%11.45%-3.68%1 Year PerformanceN/A11.50%30.61%12.14% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.55-3.8%N/AN/A$2.77M$1.10M-0.1130SNSESensei Biotherapeutics4.0699 of 5 stars$0.44-0.6%$4.33+890.7%-28.0%$11.00MN/A-0.3740TSBXTurnstone Biologics2.849 of 5 stars$0.47-1.9%$2.13+351.2%-79.7%$10.89M$19.31M-0.1582PHXMPHAXIAM TherapeuticsN/A$3.10-0.6%N/AN/A$10.58M$32.66M0.0049JAGXJaguar Health0.2557 of 5 stars$0.89-8.6%N/A-89.7%$10.46M$9.76M0.0050News CoverageGap UpINDPIndaptus Therapeutics2.868 of 5 stars$1.00flat$8.50+750.0%-49.0%$10.20MN/A-0.586CLRBCellectar Biosciences1.8001 of 5 stars$0.25-5.2%$17.67+7,067.0%-90.9%$10.17MN/A-0.1510Analyst ForecastHigh Trading VolumeMYNZMainz Biomed2.5033 of 5 stars$5.01-6.5%$120.00+2,295.2%-85.7%$10.03M$917,203.00-0.0730News CoverageGap UpCYCNCyclerion Therapeutics0.6362 of 5 stars$3.66+6.7%N/A-23.2%$9.92M$194,000.000.0030Gap DownEGRXEagle Pharmaceuticals1.0078 of 5 stars$0.75+36.4%N/A-88.5%$9.74M$257.55M0.00134Gap DownBCDABioCardia3.3021 of 5 stars$2.08flat$25.00+1,101.9%-79.8%$9.54M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap Up Related Companies and Tools Related Companies SNSE Alternatives TSBX Alternatives PHXM Alternatives JAGX Alternatives INDP Alternatives CLRB Alternatives MYNZ Alternatives CYCN Alternatives EGRX Alternatives BCDA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:MTNB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTNB Stock Alerts